The content on this site is intended for healthcare professionals only
Dr Caio Max Rocha Lima speaks to ecancer about a study carried out by the Dutch group to investigate the neoadjuvant use of gemcitabine for pancreatic and hepatobiliary cancer.
Initially, he explains the background and methodology of the study. Dr Lima then discusses the results of this study.
To conclude, he mentions the impact these results can have on the future treatment of pancreatic and hepatobiliary cancer.
Watch the meeting in full by following the links below:
Daraxonrasib plus chemotherapy shows promising first-line activity in RAS-mutant metastatic pancreatic cancer
Oncolytic adenovirus VCN-01 plus chemo shows promising survival benefit in metastatic pancreatic cancer
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepatocellular carcinoma
Durvalumab and tremelimumab show manageable safety in poor-prognosis HCC
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
